LLY

980.55

-1.5%↓

JNJ

243.38

+0.09%↑

ABBV

226.47

-0.69%↓

NVS

154.32

-0.8%↓

AZN

191.82

-0.47%↓

LLY

980.55

-1.5%↓

JNJ

243.38

+0.09%↑

ABBV

226.47

-0.69%↓

NVS

154.32

-0.8%↓

AZN

191.82

-0.47%↓

LLY

980.55

-1.5%↓

JNJ

243.38

+0.09%↑

ABBV

226.47

-0.69%↓

NVS

154.32

-0.8%↓

AZN

191.82

-0.47%↓

LLY

980.55

-1.5%↓

JNJ

243.38

+0.09%↑

ABBV

226.47

-0.69%↓

NVS

154.32

-0.8%↓

AZN

191.82

-0.47%↓

LLY

980.55

-1.5%↓

JNJ

243.38

+0.09%↑

ABBV

226.47

-0.69%↓

NVS

154.32

-0.8%↓

AZN

191.82

-0.47%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

1.18 -3.28

Buy Sell

Overview

Share price change

24h

Current

Min

1.17

Max

1.23

Key metrics
By Trading Economics
Income	-124K -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-2,364.792
Employees	161
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+82.93% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-20M 155M
Previous open	4.46
Previous close	1.18

News Sentiment

By Acuity

50%

147 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 mar 2026, 19:18 UTC

Major Market Movers

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

11 mar 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

11 mar 2026, 23:54 UTC

Market Talk

Nikkei May Decline on Energy Costs Concerns -- Market Talk

11 mar 2026, 23:51 UTC

Market Talk

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

11 mar 2026, 23:41 UTC

Market Talk

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

11 mar 2026, 23:37 UTC

Market Talk

Major News Events

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

11 mar 2026, 23:17 UTC

Major News Events

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

11 mar 2026, 23:17 UTC

Major News Events

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

11 mar 2026, 22:29 UTC

Market Talk

Australia Shares Set to Fall in Early Trade -- Market Talk

11 mar 2026, 21:47 UTC

Earnings

Liontown Resources: Market Tailwinds Strengthening Outlook

11 mar 2026, 21:46 UTC

Earnings

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

11 mar 2026, 21:45 UTC

Earnings

Liontown Resources Says FY26 Guidance Unchanged

11 mar 2026, 21:45 UTC

Earnings

Liontown Resources 1H Unit Operating Costs A$985/Ton

11 mar 2026, 21:44 UTC

Earnings

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

11 mar 2026, 21:43 UTC

Earnings

Liontown Resources 1H Revenue A$207.5 Million

11 mar 2026, 21:43 UTC

Earnings

Liontown Resources 1H Net Loss A$184 Million

11 mar 2026, 21:12 UTC

Acquisitions, Mergers, Takeovers

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

11 mar 2026, 21:10 UTC

Earnings

Vista Gold FY25 Loss $7.5M >VGZ

11 mar 2026, 21:10 UTC

Earnings

Vista Gold FY25 Loss/Shr 6c >VGZ

11 mar 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

11 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

11 mar 2026, 20:27 UTC

Acquisitions, Mergers, Takeovers

Papa John's Draws Fresh Takeover Interest -- 2nd Update

11 mar 2026, 20:26 UTC

Earnings

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

11 mar 2026, 20:19 UTC

Major News Events

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

11 mar 2026, 20:15 UTC

Earnings

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

11 mar 2026, 20:12 UTC

Major News Events

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

11 mar 2026, 19:31 UTC

Market Talk

Major News Events

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

11 mar 2026, 19:01 UTC

Market Talk

Major News Events

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

11 mar 2026, 18:59 UTC

Acquisitions, Mergers, Takeovers

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

11 mar 2026, 18:43 UTC

Major News Events

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

82.93% upside

12 Months Forecast

Average 2.25 USD 82.93%

High 2.5 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

147 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.